| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kazuyuki Takahashi, Hiroki Fujita, Naoko Fujita, Yuya Takahashi, Shunsuke Kato, Tatsunori Shimizu, Yumi Suganuma, Takehiro Sato, Hironori Waki, Yuichiro Yamad. A Pilot Study to Assess Glucose, Insulin, and Incretin Responses Following Novel High Resistant Starch Rice Ingestion in Healthy Men. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2022-06-16. PMID:35708892. |
therefore, we conducted a pilot study to assess postprandial responses of glp-1 and gip along with glucose and insulin and also gastric emptying after ingestion of the high-rs cooked rice with ss3a/be2b in healthy subjects. |
2022-06-16 |
2023-08-14 |
human |
| K M Pascutti, A L O'Kell, R C Hill, R A Castro, M E Salute, C Gilo. The effect of capromorelin on glycemic control in healthy dogs. Domestic animal endocrinology. vol 81. 2022-06-11. PMID:35689953. |
on d 1 of each treatment, blood glucose (bg), insulin, glucagon, glucose-dependent insulinotropic peptide (gip), and glucagon-like peptide-1 (glp-1) concentrations were measured before drug administration, then before and 30-120 min after feeding a glucose-rich diet (ensure plus, 21 kcal/kg). data were analyzed as a 2-period crossover design using generalized least squares estimation. capromorelin administration increased mean 48 h ig by10% and mean bg by 20% at 90 and 120 min post-prandially (p < 0.0001). |
2022-06-11 |
2023-08-14 |
Not clear |
| Han Na Jung, Yun Kyung Cho, Se Hee Min, Hwi Seung Kim, Ye-Jee Kim, Joong-Yeol Park, Woo Je Lee, Chang Hee Jun. Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison. Frontiers in endocrinology. vol 13. 2022-06-07. PMID:35669682. |
free versus fixed-ratio combination of basal insulin and glp-1 receptor agonists in type 2 diabetes uncontrolled with glp-1 receptor agonists: a systematic review and indirect treatment comparison. |
2022-06-07 |
2023-08-14 |
Not clear |
| Hui-Jun Liao, Jason T C Tze. The Potential Role of Cyclopeptides from Metabolites. vol 12. issue 5. 2022-05-28. PMID:35629891. |
the potential role of cyclopeptides from dipeptidyl peptidase 4 (dpp4) inhibitors can treat type 2 diabetes by slowing glp-1 degradation to increase insulin secretion. |
2022-05-28 |
2023-08-13 |
Not clear |
| Vivien Chavanelle, Stéphanie Chanon, Claudie Pinteur, Emmanuelle Loizon, Guillaume Vial, Yolanda F Otero, Florian Le Joubioux, Thierry Maugard, Sébastien L Peltier, Pascal Sirvent, Béatrice Mori. Impact of TOTUM-63, a fibre and polyphenol rich plant-based composition, on gut and pancreatic hormone secretion in diet-induced obese mice. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2022-05-26. PMID:35618560. |
our study aimed at exploring whether the mechanisms include modulation of gut (glucose-dependent insulinotropic peptide (gip), glucagon-like petide-1 (glp-1), cholecystokinin (cck), peptide yy (pyy)) and pancreatic (insulin, glucagon) hormones, all important regulators of glucose control, appetite and body weight. |
2022-05-26 |
2023-08-13 |
mouse |
| Ryan J Jalleh, Tongzhi Wu, Karen L Jones, Christopher K Rayner, Michael Horowitz, Chinmay S Marath. Relationships of glucose, GLP-1 and insulin secretion with gastric emptying after a 75g glucose load in type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2022-05-24. PMID:35608823. |
relationships of glucose, glp-1 and insulin secretion with gastric emptying after a 75g glucose load in type 2 diabetes. |
2022-05-24 |
2023-08-13 |
Not clear |
| Ryan J Jalleh, Tongzhi Wu, Karen L Jones, Christopher K Rayner, Michael Horowitz, Chinmay S Marath. Relationships of glucose, GLP-1 and insulin secretion with gastric emptying after a 75g glucose load in type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2022-05-24. PMID:35608823. |
the relationships of gastric emptying (ge) with the glycemic response at 120min, glp-1 and insulin secretion following a glucose load in type 2 diabetes (t2d) are uncertain. |
2022-05-24 |
2023-08-13 |
Not clear |
| Mariusz Nowak, Wojciech Nowak, Władysław Grzeszcza. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Endokrynologia Polska. 2022-05-20. PMID:35593668. |
the incretin hormones glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are responsible for up to 65% of postprandial insulin secretion. |
2022-05-20 |
2023-08-13 |
Not clear |
| Petr Busek, Jonathan S Duke-Cohan, Aleksi Sed. Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? Cancers. vol 14. issue 9. 2022-05-14. PMID:35565202. |
specific dpp-iv inhibitors (gliptins) are currently used in patients with type 2 diabetes mellitus to promote insulin secretion by prolonging the activity of the incretins glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip). |
2022-05-14 |
2023-08-13 |
Not clear |
| Landon Deru, Cali Warren, Braxton Wright, Jacob Coleman, Austin Duersch, Hi'ilei Chan, Katelynn Hales, Bruce Bailey, Benjamin Bikma. Understanding the endocrine response to macronutrients in the context of a ketogenic diet. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 36 Suppl 1. 2022-05-13. PMID:35552192. |
thirteen analytes were measured including amylin, c-peptide, ghrelin, gastric inhibitory peptide (gip), glucagon, glucagon-like peptide 1 (glp-1), interleukin 6 (il-6), insulin, leptin, pancreatic polypeptide (pp), polypeptide yy (pyy), and tumor necrosis factor alpha (tnf). |
2022-05-13 |
2023-08-13 |
human |
| Landon Deru, Cali Warren, Braxton Wright, Jacob Coleman, Austin Duersch, Hi'ilei Chan, Katelynn Hales, Bruce Bailey, Benjamin Bikma. Understanding the endocrine response to macronutrients in the context of a ketogenic diet. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 36 Suppl 1. 2022-05-13. PMID:35552192. |
amylin, c-peptide, gip, glucagon, glp-1, insulin, and mcp-1 each demonstrated a statistically significant difference between conditions (p = 0.0298 for mcp-1, p<0.0001 for all others). |
2022-05-13 |
2023-08-13 |
human |
| Jessica M Ferrell, Matthew Dilts, Zachary Stahl, Sabita Pokhrel, Shannon Boehme, John Y L Chian. The Bile Acid Receptor Tgr5 and High Fat, High Sugar-Induced Liver Injury. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 36 Suppl 1. 2022-05-13. PMID:35553888. |
tgr5 also induces glp-1 secretion from enterocytes to improve insulin sensitivity. |
2022-05-13 |
2023-08-13 |
Not clear |
| Yimei Shen, Xiaohua Yang, Xiaojun Han, Wei Xi, Lihua Jiang, Shuqin Wang, Haifeng Zhong, Yunjuan G. Erratum: Influence of GLP-1 receptor agonist on insulin dosage and blood glucose control of patients with type 2 diabetes mellitus. American journal of translational research. vol 14. issue 4. 2022-05-13. PMID:35559423. |
erratum: influence of glp-1 receptor agonist on insulin dosage and blood glucose control of patients with type 2 diabetes mellitus. |
2022-05-13 |
2023-08-13 |
Not clear |
| Tomohiko Kimura, Kohei Kak. Clinical relevance of dual agonist of glucagon and GLP-1 receptors to achieve functional restoration of first and second phase insulin secretion. Journal of diabetes investigation. 2022-05-11. PMID:35543083. |
clinical relevance of dual agonist of glucagon and glp-1 receptors to achieve functional restoration of first and second phase insulin secretion. |
2022-05-11 |
2023-08-13 |
Not clear |
| Kazuho Inoue, Shohei Yamada, Seiko Hoshino, Minoru Watanabe, Kenjiro Kimura, Atsuko Kamijo-Ikemor. Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats. BMC ophthalmology. vol 22. issue 1. 2022-05-06. PMID:35524186. |
this study aims to investigate the effect of the glucagon-like peptide-1 (glp-1) receptor agonist (glp-1ra) liraglutide on retinal pathological findings as compared with insulin and hydralazine using an animal model of type 2 diabetes with obesity, hypertension, and hyperlipidemia. |
2022-05-06 |
2023-08-13 |
rat |
| Timothy S Bailey, Jasvinder Gill, Merwyn Jones, Laxmi Shenoy, Charlie Nicholls, Jukka Westerback. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study. Diabetes, obesity & metabolism. 2022-05-02. PMID:35491520. |
real-world outcomes of addition of insulin glargine 300 u/ml (gla-300) to glp-1 ra therapy in people with type 2 diabetes: the deliver-g study. |
2022-05-02 |
2023-08-13 |
Not clear |
| Timothy S Bailey, Jasvinder Gill, Merwyn Jones, Laxmi Shenoy, Charlie Nicholls, Jukka Westerback. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study. Diabetes, obesity & metabolism. 2022-05-02. PMID:35491520. |
in people with type 2 diabetes mellitus (pwd2) suboptimally controlled with glp-1 receptor agonist (glp-1 ra) therapy, addition of basal insulin (bi) is recommended. |
2022-05-02 |
2023-08-13 |
Not clear |
| Kyung Jin Choi, Jin Wook Hwang, Se Hoon Kim, Hyung Seo Par. Ca The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology. vol 26. issue 3. 2022-04-28. PMID:35477549. |
ca glucagon like peptide-1 (glp-1) released from enteroendocine l-cells in the intestine has incretin effects due to its ability to amplify glucose-dependent insulin secretion. |
2022-04-28 |
2023-08-13 |
Not clear |
| Antonio J López-Gambero, Beatriz Pacheco-Sánchez, Cristina Rosell-Valle, Dina Medina-Vera, Juan Antonio Navarro, María Del Mar Fernández-Arjona, Marialuisa de Ceglia, Carlos Sanjuan, Vincent Simon, Daniela Cota, Patricia Rivera, Fernando Rodríguez de Fonseca, Juan Suáre. Dietary administration of D-chiro-inositol attenuates sex-specific metabolic imbalances in the 5xFAD mouse model of Alzheimer's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 150. 2022-04-28. PMID:35483188. |
dci also partially normalized impaired insulin signaling and circulating insulin, glp-1, and gip deficiencies in 5xfad mice. |
2022-04-28 |
2023-08-13 |
mouse |
| Maria F Fernandes, Michelle V Tomczewski, Robin E Dunca. Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid. International journal of molecular sciences. vol 23. issue 8. 2022-04-23. PMID:35456981. |
glucagon-like peptide-1 (glp-1) potentiates glucose-stimulated insulin secretion (gsis). |
2022-04-23 |
2023-08-13 |
mouse |